AGIO Agios Pharmaceuticals Inc.

Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020

Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m. ET to report its second quarter 2020 financial results and other business highlights.

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 2955575. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.

About Agios

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at

Contacts

Investors:

Holly Manning, 617-844-6630

Director, Investor Relations

Media:

Jessica Rennekamp, 857-209-3286

Associate Director, Corporate Communications

EN
16/07/2020

Underlying

AGIOAgios Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agios Pharmaceuticals Inc.

 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Con...

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET. The live webcast will be accessible on the Investors section of the company's website () under the “Events & Presentations” tab. A replay of the w...

May 9, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios to Present at the BofA Securities 2025 Health Care Conference on...

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. The live webcast will be accessible on the Investors section of the company's website () under the “Events & Presentations” tab. A replay of the webcast w...

May 2, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Reports First Quarter 2025 Financial Results and Recent Business...

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities ...

May 1, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios to Webcast Conference Call of First Quarter Financial Results on...

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET to report its first quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website () under the “Events & Presen...

April 17, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) t...

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company’s 2023 Stock Incentive Plan to its newly appointed Chief Corporate Development & Strategy Officer, Krishnan Viswanadhan. The grants were approved by the Board of Directors effect...

March 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch